Exploring Current and Future Trends in Lentiviral Vector Manufacturing
Lentiviral vector (LVV) design involves selecting a suitable backbone, promoter, and enhancer sequences to drive gene expression in the targeted cells. To successfully package such vectors, transgene of interest, regulatory elements, and packaging signal are all essential components.
Furthermore, the LVV manufacturing process involves multiple steps and challenges that must be carefully addressed to unlock the full potential of LVV-based cell and gene therapies. As advancements continue, overcoming these challenges will pave the way for broader clinical applications and improved patient outcomes.
This roundtable discussion draws together acknowledged experts from the fields of LVV design, manufacture, and regulation to examine the key current trends in the space and point the way to future success.
- Review the current status of the LVV-based cell and gene therapy field
- Uncover the role of plasmid DNA as a starting material
- Address challenges in LVV manufacturing
- Overcome QC and regulatory hurdles
About the Presenters
Aaron Vernon
Chief Manufacturing Officer, Quell Therapeutics
Palani Palaniappan
Chief Technology Officer, Flagship Pioneering
Philip Vanek
Chief Technology Officer, Gamma Biosciences
Scott Cross
Senior Principal, Head of Gene Therapy CMC, Dark Horse Consulting, Inc.
Ramin Baghirzade
Global Commercial Head Gene Therapy, Charles River Laboratories
Lentivation™ Sets a Course for Rapid Gene Therapy Manufacturing
By integrating the three pillars of plasmid DNA, lentiviral vector production, and testing, the Lentivation™ platform enables therapeutic developers to get to GMP up to 60% faster than traditional manufacturing timelines.
Power Your Program